AI in Healthcare 2025

Tern plc

The year 2025 marked a significant shift in the integration of artificial intelligence into healthcare, as the technology moved from experimental phases into active use across clinical and commercial settings. AI, once viewed as a long-term prospect, began delivering practical benefits, with healthcare organisations adopting it to streamline operations, enhance patient communication and improve medical outcomes.

Throughout the year, generative AI was deployed more widely in hospitals, clinics and pharmaceutical companies. Clinical teams used it to produce care plans and patient notes in real time, reducing time spent on documentation and allowing more focus on decision-making and patient care. Predictive AI was applied to flag potential hospital readmissions and other risks before they materialised, contributing to efficiency gains and better patient outcomes. At the same time, AI-generated, multi-language patient education materials helped address gaps in communication, particularly for underserved populations.

In the pharmaceutical and healthcare marketing sectors, data intelligence and targeting technologies helped refine how companies engaged with both clinicians and patients. Rather than relying on broad messaging, marketers used AI-driven insights to tailor communications more precisely, increasing engagement and improving return on investment.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search